ZVRA ZEVRA THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1434647 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY75.1%
TTM net income YoY120.8%
TTM EPS YoY159.6%
Revenue 3-yr CAGR106.2%
Net income 3-yr CAGR—
Margins
Gross margin95.4%
Operating margin60.8%
Net margin52.8%
FCF margin25.9%
EBITDA margin61.8%
Returns
ROE41.9%
ROA26.7%
ROIC (approx.)60.6%
Asset turnover0.51x
Leverage & solvency
Liabilities / assets23.8%
Debt / equity0.00x
Current ratio5.46x
Interest coverage24.55x
Cash quality & payout
Operating cash flow / net income0.50x
Accruals ratio13.5%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $37.76M | $39.66M | $36.22M | $34.12M | $26.06M | $25.88M | $20.40M | $12.04M |
| Cost of revenue | $1.79M | $1.52M | $1.90M | $1.52M | $1.24M | $12.38M | $1.34M | $1.37M |
| Gross profit | $35.96M | $38.14M | $34.32M | $32.60M | $24.82M | $13.50M | $19.06M | $10.68M |
| R&D expense | $4.94M | $4.49M | $4.39M | $2.62M | $3.43M | $3.43M | $3.26M | $8.35M |
| SG&A expense | $19.13M | $16.56M | $20.78M | $20.35M | $16.93M | $20.78M | $19.55M | $16.12M |
| Operating income | $11.58M | $16.78M | $52.15M | $9.31M | $4.14M | -$71.04M | -$5.36M | -$15.42M |
| Interest expense | $0 | $0 | $1.71M | $1.95M | $2.05M | $2.01M | $1.97M | $2.19M |
| Pretax income | $19.72M | $12.79M | $44.80M | $12.67M | -$977,000 | $76.91M | -$1.92M | -$20.37M |
| Income tax | $510,000 | $4.04M | $6.91M | $501,000 | -$433,000 | $2.20M | $1.18M | $15.37M |
| Net income | $19.21M | $8.75M | $37.89M | $12.16M | -$544,000 | $74.71M | -$3.10M | -$35.74M |
| EBITDA | $11.96M | $17.14M | $52.51M | $9.68M | $4.54M | -$69.39M | -$3.71M | -$13.77M |
| EPS (basic) | 0.31 | 0.14 | 0.62 | — | -0.01 | 1.24 | -0.06 | — |
| EPS (diluted) | 0.26 | 0.14 | 0.60 | — | -0.01 | 1.21 | -0.06 | — |
| Weighted avg. shares (diluted) | 61.73M | 61.34M | 60.23M | — | 55.95M | 56.32M | 54.10M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $122.15M | $145.32M | $95.59M | $62.41M | $54.44M | $47.71M | $37.34M | $33.78M |
| Short-term investments | $73.42M | $76.25M | $105.02M | $128.60M | $145.07M | $154.90M | $25.29M | $35.71M |
| Receivables | — | — | — | — | — | — | — | $10.18M |
| Inventory | $3.07M | $2.45M | $2.31M | $1.74M | $1.37M | $1.11M | $2.56M | $1.97M |
| Current assets | $225.84M | $251.30M | $229.97M | $223.01M | $225.12M | $226.34M | $81.57M | $86.03M |
| PP&E, net | $816,000 | $641,000 | $430,000 | $489,000 | $488,000 | $599,000 | $422,000 | $356,000 |
| Goodwill | $4.70M | $4.70M | $4.70M | $4.70M | $4.70M | $4.70M | $4.70M | $4.70M |
| Intangibles | $5.47M | $5.79M | $6.11M | $6.42M | $6.74M | $7.05M | $67.38M | $68.99M |
| Total assets | $313.57M | $302.71M | $278.58M | $284.73M | $270.12M | $256.28M | $172.71M | $178.13M |
| Current liabilities | $41.37M | $48.63M | $47.03M | $39.28M | $26.11M | $28.83M | $26.98M | $34.06M |
| Long-term debt | $0 | $0 | $0 | $61.93M | $61.31M | $60.69M | $60.09M | $59.50M |
| Total debt | $0 | $0 | $0 | $61.93M | $61.31M | $60.69M | $60.09M | $59.50M |
| Total liabilities | $74.65M | $85.06M | $72.78M | $130.07M | $136.95M | $139.05M | $131.69M | $138.46M |
| Shareholders' equity | $238.92M | $217.65M | $205.80M | $154.66M | $133.16M | $117.23M | $41.02M | $39.67M |
| Net debt | -$122.15M | -$145.32M | -$95.59M | -$478,000 | $6.87M | $12.98M | $22.75M | $25.72M |
| Shares outstanding | 59.44M | 59.34M | 59.11M | 56.85M | 56.22M | 55.08M | 54.68M | 53.67M |
| Cash flow statement | ||||||||
| Operating cash flow | $10.05M | $17.03M | $6.14M | $5.52M | $4.71M | -$3.60M | -$8.22M | -$16.25M |
| Capital expenditure | $238,000 | $217,000 | $35,000 | -$31,000 | $554,000 | $213,000 | $99,000 | $0 |
| Free cash flow | $9.81M | $16.82M | $6.11M | $5.55M | $4.16M | -$3.81M | -$8.32M | -$16.25M |
| Investing cash flow | -$34.85M | $31.45M | $79.62M | $227,000 | -$4.58M | $11.93M | $10.54M | -$5.47M |
| Financing cash flow | $1.55M | $1.58M | -$52.80M | $2.55M | $6.53M | $1.38M | $1.61M | $796,000 |
| Depreciation & amortization | $378,000 | $364,000 | $368,000 | $362,000 | $392,000 | $1.65M | $1.65M | $1.65M |
| Stock-based compensation | $2.67M | $2.97M | $3.10M | $4.28M | $2.77M | $2.46M | $3.12M | $4.02M |
| Share buybacks | — | — | — | — | — | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 52 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.